AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues
First Full Year Growth Since 2011
With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat.
